Pattern of metastatic spread in triple-negative breast cancer - PubMed (original) (raw)
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent et al. Breast Cancer Res Treat. 2009 May.
Abstract
Purpose: The prognosis of women with triple-negative breast cancers (defined as cancers that are estrogen receptor-negative, progesterone receptor-negative and HER2/neu negative) is poor, compared to women with other subtypes of breast cancer. It is proposed that the underlying difference in recurrence rates may be explained in part by different routes of metastatic spread.
Experimental design: We studied a cohort of 1608 patients diagnosed with breast cancer, diagnosed between January 1987 and December 1997 at Women's College Hospital in Toronto. Triple-negative breast cancers were defined as those that were estrogen receptor-negative, progesterone receptor-negative and HER2/neu-negative. We compared the incidence rates of metastatic spread to bone and to other (non-bone) organs in women with triple-negative and other forms of breast cancer.
Results: Of the 1,608 patients, 180 (11.2%) had triple-negative breast cancer. The 1608 women were followed for a median of 9.0 years (range 0.1-19 years). Compared to other patients, those with triple-negative breast cancer had an increased likelihood of distant recurrence over the study period (adjusted hazard ratio (HR) 1.9; 95% CI: 1.5-2.5, P < 0.0001). The relatively poor prognosis was apparent in the five years after diagnosis (HR 2.9; 95% CI: 2.1-3.9; P = 0.0001) but not thereafter (HR 0.5; 95% CI: 0.2-1.1; P = 0.07). In particular, women with triple-negative breast cancer were four times more likely to experience a visceral metastasis within five years of diagnosis than those with other types of cancer (HR 4.0; 95% CI: 2.7-5.9; P < 0.0001). The rates of bone metastases were comparable for triple-negative and for other forms of cancer in this time period (HR 0.8; 95% CI: 0.4-1.6 P = 0.5).
Conclusions: The excess risk of distant recurrence in triple-negative breast cancers, versus other forms of cancer, is attributable in large part to an excess of visceral metastases in the first five years following diagnosis.
Similar articles
- Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. Haffty BG, et al. J Clin Oncol. 2006 Dec 20;24(36):5652-7. doi: 10.1200/JCO.2006.06.5664. Epub 2006 Nov 20. J Clin Oncol. 2006. PMID: 17116942 - Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A. Heitz F, et al. Eur J Cancer. 2009 Nov;45(16):2792-8. doi: 10.1016/j.ejca.2009.06.027. Epub 2009 Jul 28. Eur J Cancer. 2009. PMID: 19643597 - T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
Kaplan HG, Malmgren JA, Atwood M. Kaplan HG, et al. Breast J. 2009 Sep-Oct;15(5):454-60. doi: 10.1111/j.1524-4741.2009.00789.x. Epub 2009 Aug 4. Breast J. 2009. PMID: 19671105 - What is triple-negative breast cancer?
Irvin WJ Jr, Carey LA. Irvin WJ Jr, et al. Eur J Cancer. 2008 Dec;44(18):2799-805. doi: 10.1016/j.ejca.2008.09.034. Epub 2008 Nov 12. Eur J Cancer. 2008. PMID: 19008097 Review. - Triple-negative breast cancer: a short review.
Elias AD. Elias AD. Am J Clin Oncol. 2010 Dec;33(6):637-45. doi: 10.1097/COC.0b013e3181b8afcf. Am J Clin Oncol. 2010. PMID: 20023571 Review.
Cited by
- A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
Zhang J, Wang L, Wang Z, Hu X, Wang B, Cao J, Lv F, Zhen C, Zhang S, Shao Z. Zhang J, et al. Cancer Biol Ther. 2015;16(2):225-32. doi: 10.4161/15384047.2014.986973. Cancer Biol Ther. 2015. PMID: 25648299 Free PMC article. Clinical Trial. - Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.
Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S, Arpino G. Malorni L, et al. Breast Cancer Res Treat. 2012 Dec;136(3):795-804. doi: 10.1007/s10549-012-2315-y. Epub 2012 Nov 4. Breast Cancer Res Treat. 2012. PMID: 23124476 Free PMC article. - Non-sentinel lymph node metastases risk factors in patients with breast cancer with one or two sentinel lymph node macro-metastases.
Xu LY, Zhao J, Wang X, Jin XY, Wang BB, Fan YY, Pei XH. Xu LY, et al. Heliyon. 2023 Oct 24;9(11):e21254. doi: 10.1016/j.heliyon.2023.e21254. eCollection 2023 Nov. Heliyon. 2023. PMID: 37964832 Free PMC article. - Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy.
López-Ozuna VM, Hachim IY, Hachim MY, Lebrun JJ, Ali S. López-Ozuna VM, et al. Sci Rep. 2016 Aug 2;6:30934. doi: 10.1038/srep30934. Sci Rep. 2016. PMID: 27480353 Free PMC article. - Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.
Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Cardoso F. Metzger-Filho O, et al. J Clin Oncol. 2013 Sep 1;31(25):3083-90. doi: 10.1200/JCO.2012.46.1574. Epub 2013 Jul 29. J Clin Oncol. 2013. PMID: 23897954 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous